The proposal was designed to address three issues. First could we identify stem cells fromthe fallopian tube, including from patients with high grade serous cancer HGSC. Second,could we link the molecular abnormalities in cancer associated stem cells and validate themin pathologic material, specifically in what we feel are stem cell outgrowths or SCOUTs andthird could we identify molecular alterations that would place the oviduct or the patient atrisk for HGSC. In essence we wished to drill down to the cell of origin and link it to cancerrisk, identifying an assay that could predict the presence of cancer by analyzing lowergenital tract fluids or other samples. All of these aims have been addressed and our studieshave reinforced the likelihood that novel pathways to ovarian cancer exist, but evidencepoints to more than one mechanism and site of origin.